Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Despite legal hassles, JnJ beats profit estimates on pharma strength

      Despite legal hassles, JnJ beats profit estimates on pharma strength

      Medical Dialogues Bureau17 July 2019 12:10 PM IST
      Johnson and Johnson's (JnJ) pharmaceuticals unit has cushioned the impact of slow growth in its medical device and consumer health units, largely due...
      Abbott to increase production of lower-cost glucose monitors as diabetes soars

      Abbott to increase production of lower-cost glucose monitors as diabetes soars

      Medical Dialogues Bureau17 July 2019 9:30 AM IST
      CHICAGO: Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to...
      Novartis sickle cell drug crizanlizumab secures speedy USFDA review

      Novartis sickle cell drug crizanlizumab secures speedy USFDA review

      Medical Dialogues Bureau17 July 2019 9:26 AM IST
      Novartis submitted the application for crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) and...
      Takeda Pharma launches Rare Disease Therapies in India

      Takeda Pharma launches Rare Disease Therapies in India

      Medical Dialogues Bureau17 July 2019 9:25 AM IST
      Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a...
      USFDA issues warning letter to Indoco Remedies for Goa plant

      USFDA issues warning letter to Indoco Remedies for Goa plant

      Medical Dialogues Bureau16 July 2019 11:39 AM IST
      The facility had received six observations in Form 483s and was classified as Official Action Indicated in March. Indoco Remedies responded to these...
      Natco Pharma gets zero USFDA observations for Chennai facility

      Natco Pharma gets zero USFDA observations for Chennai facility

      Medical Dialogues Bureau16 July 2019 9:30 AM IST
      Natco Pharma announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical...
      GSK drug Zejula helps ovarian cancer patients live longer in late-stage study

      GSK drug Zejula helps ovarian cancer patients live longer in late-stage study

      Medical Dialogues Bureau16 July 2019 9:26 AM IST
      GSK bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian...
      AstraZeneca Farxiga fails to win USFDA approval for Type-1 diabetes

      AstraZeneca Farxiga fails to win USFDA approval for Type-1 diabetes

      Medical Dialogues Bureau16 July 2019 9:25 AM IST
      AstraZeneca said USFDA issued a complete response letter, declining its application for using the drug in patients with Type-1 diabetes where insulin...
      Boehringer buys up AMAL Therapeutics, eyes oncology combo strategy

      Boehringer buys up AMAL Therapeutics, eyes oncology combo strategy

      Medical Dialogues Bureau16 July 2019 9:15 AM IST
      The total transaction could amount up to EUR 325 million and is comprised of upfront payment as well as contingent clinical, development and...
      GSK to appoint Novartis, Astrazeneca ex-executive Jonathan Symonds as new Chairman: Bloomberg

      GSK to appoint Novartis, Astrazeneca ex-executive Jonathan Symonds as new Chairman: Bloomberg

      Medical Dialogues Bureau15 July 2019 2:29 PM IST
      The appointment of Jonathan Symonds, currently the deputy chairman at HSBC Holdings Plc, still needs to be finalized and is subject to approval from...
      Lupin to focus on launch of biosimilar, inhalation product in US this fiscal

      Lupin to focus on launch of biosimilar, inhalation product in US this fiscal

      Medical Dialogues Bureau15 July 2019 9:45 AM IST
      Coupling this with the building of Solosec brand in the US, NaMuscla in Europe and Bipresso in Japan will help Lupin drive sustainable growth, they...
      Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report

      Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report

      Medical Dialogues Bureau15 July 2019 9:30 AM IST
      The deal is the largest Gilead has executed since new Chief Executive Officer Dan O'Day took the reins in March as he attempts to bolster the San...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok